Competence Centre on Health Technologies
Follow us on

beREADY - endometrial receptivity test

The endometrial receptivity test is a personalized medicine tool for advanced IVF. The test is designed for all women undergoing IVF treatment because all patients deserve the best treatment
The test guarantees that your embryo(s) are transferred in time, and your optimal timing is defined
The personalised medicine increases YOUR chance of getting pregnant and saves your embryos, time, and money

Benefits of endometrial receptivity test

71.2%

Did you know that 71.2% of patients gave birth after the first year of IVF treatment using the endometrial receptivity test*?

72.5%

Please note that 72.5% pregnancy rate was achieved by the first IVF cycle when endometrial receptivity test was used*

Fourfold live birth rate increase acheived among RIF patients after endometrial receptivity testing**

Have you experienced IVF failure?

Please consider using an endometrial receptivity test to observe your Window Of Implantation (WOI). This information increases your chance of pregnancy because correct timing is relevant in IVF
We recommend the beREADY test for all patients but especially for patients who have already experienced implantation failure. Our study shows a 56.7% pregnancy rate among implantation failure patients after applying the test
Our test has unprecedented accuracy and sensitivity because it detects biomarkers at a single-molecule level. beREADY test provides the most precise diagnosis and embryo transfer time***
Did you know that 1 out of 3 patients experience IVF failure because the embryo is transferred too early or too late?****

What does personalised medicine mean in IVF?

Genes make us different, and IVF treatment is no exception. About 30% of women have displaced Window Of Implantation (WOI) compare to average. These patients need a personalized plan because the "average" does not work for all
Your endometrial readiness is affected by your genes and its mediated individual drug response. It means that drug response influence your endometrial readiness and implantation rate after embryo transfer
The study showed that a personalized IVF treatment plan increased cumulative pregnancy rate up to 94%*. That is why you deserve advanced medicine and higher success rates

What does the beREADY test show?

The test measures the maturity level of your endometrium. The information you get enables embryo transfer at the optimal time. The results may show three possible scenarios with probability percent. 42% of beREADY patients have pre- or early-receptive diagnose and they need more time to mature. About half of the patients have an "average" maturation speed, and approximately 10% need less time for maturation compare to "average". As you see it is difficult to make a diagnosis without testing

42%
PRE or EARLY-RECEPTIVE

You need more time! The test shows that you have shifted WOI, and embryo transfer should be done later. So, the report indicates the exact timing that is optimal for you

49%
FULLY-RECEPTIVE

The test confirms that you have an average and expected WOI and there is no need to change the timing

9%
LATE or POST-RECEPTIVE

You have rapid endometrial maturation! The test shows that you have shifted WOI, and embryo transfer should be done earlier. So, the report indicates the exact timing that is optimal for you

How does the beREADY test work?

Endometrial sample

Sample shipping to beREADY lab

Sample processing and quality control

beREADY analysis and reporting

Embryo transfer at the right time

Results are available in 1-2 weeks

Comparison of endometrial receptivity tests

The beREADY test is developed based on carefully classified samples and independent clinical validation.

As a comparison, 45 HRT patients’ samples were involved in a comparison against the Endometrial Receptivity Analysis (ERA, Igenomix) test. The concordance rate between the two tests is as high as 96% because the same tissue samples were analyzed.

The beREADY test applies novel and highly accurate TAC-seq DNA sequencing technology. The technology enables the detection of biomarker molecules at a single-molecule level and provides ultimate sensitivity.

patented

beREADY test uses highly sensitive and patented TAC-seq technology because only that approach ensures accuracy. The original data analysis algorithm is published*** and adjusted later to beREADY diagnostic assay.

Referred publications and research behind beREADY test

* Simón et al., A 5-year Multicenter Randomized Controlled Trial of In Vitro Fertilization with Personalized Blastocyst Transfer versus  Frozen or Fresh Transfer. 2020, Reproductive BioMedicine Online, PubMed ID 32723696. Link to original study

** Haouzi et al., Customized Frozen Embryo Transfer after Identification of the Receptivity Window with a Transcriptomic Approach Improves the Implantation and Live Birth Rates in Patients with Repeated Implantation Failure. 2021, Reproductive Sciences, PubMed ID 32725589Link to original study

*** Teder et al., TAC-seq: targeted DNA and RNA sequencing for precise biomarker molecule counting. 2018, npj Genomic Medicine, PubMed ID 30588329. Link to original study

**** Ruiz-Alonso et al., The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure. 2013, Fertility and Sterility, PubMed ID 23756099. Link to original study

Saare et al., A molecular tool for menstrual cycle phase dating in endometriosis transcriptomic studies. 2019, Biology of Reproduction, PubMed ID 31004479. Link to original study

Suhorutshenko et al., Endometrial receptivity revisited: endometrial transcriptome adjusted for tissue cellular heterogeneity. 2018, Human Reproduction, PubMed ID 30295736. Link to original study

Altmäe et al., Meta-signature of human endometrial receptivity: a meta-analysis and validation study of transcriptomic biomarkers. 2018, Scientific Reports, PubMed ID 28855728. Link to original study

Krjutškov et al., Single-cell transcriptome analysis of endometrial tissue. 2016, Human Reproduction, PubMed ID 26874359. Link to original study